Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15717177 | 1.00 | NTRK1 (0.39) | NTRK1HTR2AHTR2CGAASMN1; SMN2 | |
| SCHEMBL29139839 | 1.00 | NTRK1 (0.39) | NTRK1HTR2AHTR2CGAASMN1; SMN2 | |
| SCHEMBL30659759 | 1.00 | NTRK1 (0.39) | NTRK1HTR2AHTR2CGAASMN1; SMN2 | |
| SCHEMBL15717022 | 1.00 | NTRK1 (0.39) | NTRK1HTR2AHTR2CGAASMN1; SMN2 | |
| SCHEMBL29139826 | 1.00 | NTRK1 (0.39) | NTRK1HTR2AHTR2CGAASMN1; SMN2 | |
| SCHEMBL30659732 | 1.00 | NTRK1 (0.39) | NTRK1HTR2AHTR2CGAASMN1; SMN2 | |
| Tartaric Acid SCHEMBL30659754 | 0.86 | NTRK1 (0.40) | NTRK1GAASMN1; SMN2NOTUM | |
| Cadaverine Tartrate SCHEMBL30659719 | 0.86 | NTRK1 (0.40) | NTRK1GAASMN1; SMN2NOTUM | |
| SCHEMBL18293095 | 0.80 | NTRK1 (0.40) | NTRK1HTR2AHTR2CGAASMN1; SMN2 | |
| SCHEMBL21553484 | 0.80 | HTR2A (0.38) | HTR2AHTR2CGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417384-A1 | CRYSTALS OF TETRAHYDRONAPHTHYL UREA DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-12-19 | — | — | US | disclosed |
| US-12134607-B2 | Crystals of tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-05 | — | — | US | disclosed |
| EP-3617195-B1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVES AS INHIBITORS OF TROPOMYOSIN RECEPTOR KINASE A FOR THE TREATMENT OF PAIN | MOCHIDA PHARM CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-110831926-B | Tetrahydronaphtyl urea derivatives | 持田制药株式会社 | 2023-11-21 | — | — | CN | disclosed |
| US-20220348552-A1 | CRYSTALS OF TETRAHYDRONAPHTHYL UREA DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-11-03 | — | — | US | disclosed |
| US-11325895-B2 | Crystals of tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-05-10 | — | — | US | disclosed |
| US-10927079-B2 | Intermediate compound of novel tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-23 | — | — | US | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200308136-A1 | CRYSTALS OF TETRAHYDRONAPHTHYL UREA DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2020-10-01 | — | — | US | disclosed |
| US-20200239419-A1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10399945-B2 | Tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2019-09-03 | — | — | US | disclosed |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190023657-A1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| US-20160355521-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2016-12-08 | — | — | US | disclosed |
| EP-2920166-B1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2920166-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | Array Biopharma, Inc. (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014078454-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20070015761-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-01-18 | — | — | US | disclosed |
| WO-2006108713-A2 | 1-AMINO-1, 2,3,4-TETRAHYDRO-NAPHTHALINE-2-OL DERIVATES AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239419-A1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE | CCNT2, UTS2R, DIMT1 | NTRK1 4053/4885HTR2A 1139/4885HTR2C 1294/4885 |
| US-20240417384-A1 | CRYSTALS OF TETRAHYDRONAPHTHYL UREA DERIVATIVE | ULK2, UTS2R, UMPS | NTRK1 11/4885HTR2A 112/4885HTR2C 42/4885 |
| US-20220348552-A1 | CRYSTALS OF TETRAHYDRONAPHTHYL UREA DERIVATIVE | ULK2, UTS2R, UMPS | NTRK1 11/4885HTR2A 112/4885HTR2C 42/4885 |
| US-20070015761-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | DHPS, TNF, PTGES | NTRK1 4526/4885HTR2A 1388/4885HTR2C 1682/4885 |
| US-10927079-B2 | Intermediate compound of novel tetrahydronaphthyl urea derivative | CCNT2, DIMT1, QTRT2 | NTRK1 3924/4885HTR2A 1064/4885HTR2C 1017/4885 |
| US-11325895-B2 | Crystals of tetrahydronaphthyl urea derivative | ULK2, UTS2R, UMPS | NTRK1 11/4885HTR2A 112/4885HTR2C 42/4885 |
| US-10399945-B2 | Tetrahydronaphthyl urea derivative | OPRL1, TRPV1, TSLP | NTRK1 6/4885HTR2A 910/4885HTR2C 1142/4885 |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | NTRK1 79/4885HTR2A 1325/4885HTR2C 1478/4885 |
| US-20200308136-A1 | CRYSTALS OF TETRAHYDRONAPHTHYL UREA DERIVATIVE | ULK2, UTS2R, UMPS | NTRK1 11/4885HTR2A 112/4885HTR2C 42/4885 |
| US-12134607-B2 | Crystals of tetrahydronaphthyl urea derivative | ULK2, UTS2R, UMPS | NTRK1 11/4885HTR2A 112/4885HTR2C 42/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | NTRK1 79/4885HTR2A 1325/4885HTR2C 1478/4885 |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | NTRK1 79/4885HTR2A 1325/4885HTR2C 1478/4885 |
| US-20160355521-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | NTRK1 79/4885HTR2A 1325/4885HTR2C 1478/4885 |
| US-20190023657-A1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE | UTS2R, OPRL1, TRPV1 | NTRK1 18/4885HTR2A 971/4885HTR2C 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.